On the origins of three-dimensionality in drug-like molecules

webinar

Thu, 20 Oct 2016, 17:00 CEST (Berlin)

Dr. Nathan Brown, The Institute of Cancer Research, London, UK

On the origins of three-dimensionality in drug-like molecules

Many medicinal chemistry-relevant structures and core scaffolds tend toward geometric planarity, which hampers the optimization of physicochemical properties desirable in drug-like molecules. As challenging drug target classes emerge, the exploitation of molecular three-dimensionality in lead optimization is becoming increasingly important. While recent interest has emphasized the importance of enhanced three-dimensionality in molecular fragment designs, the extent to which this is required in core scaffolds remains unclear.

Three computational methods, Scaffold Tree deconstruction, Synthetic Disconnection Rules retrosynthetic deconstruction and virtual library enumeration, are applied, together with the descriptors plane of best fit and principal moments of inertia, to investigate the origins of three-dimensionality in drug-like molecules. This study informs on the stage at which molecular three-dimensionality should be considered in drug design and highlights key learning that is anticipated to enhance medicinal chemistry design in the future.

Current news

category
Events
Recordings of the BioSolveIT Day 2025 Available
October 15, 2025 13:39 CEST
Missed BioSolveIT Day 2025? The recordings from BioSolveIT Day 2025 are now live! Packed with practical insights for medicinal and computational chemists, the sessions showcase how SeeSAR, infiniSee, Chemical Space Docking®, and CoLibri accelerate real-world discovery, from pocket-aware design and HYDE-guided decisions to trillion-scale, synthesizable chemical space exploration and in-house...
Read on
Enamine’s REAL Space September 2025 Update - Now 83 Billion!
September 23, 2025 10:31 CEST
The September 2025 update of Enamine’s REAL Space brings a new expansion, now featuring over 83 billion accessible, drug-like products, up from 76 billion in the previous release. Built from 172 curated reactions and 192,487 reagents and building blocks based on in-house knowledge, this version further enhances one of the...
Read on
WuXi’s GalaXi Space September 2025 – Expanded to 26 Billion Molecules!
September 17, 2025 10:03 CEST
The September 2025 update of WuXi LabNetwork’s GalaXi Space delivers a major expansion, now featuring over 25.8 billion synthesis-ready products. Built from 185 curated reactions and 30,877 high-quality building blocks, GalaXi is one of the largest tangible Chemical Spaces for modern drug discovery. This release broadens structural diversity with novel...
Read on